LONDON (Reuters) - A hot new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein called PD-1 is going to be big - but not nearly as big as investors think, according to a new analysis.
via Reuters: Health News Read More Here..
No comments:
Post a Comment